Myomo Appoints New Chief Commercial Officer to Drive Payer Coverage Expansion

What happened

Myomo announced the appointment of Mary-Katherine McClure as Chief Commercial Officer, effective October 12, 2026, succeeding Micah Mitchell who will depart after a transition period. The change comes as Myomo continues to scale under the Medicare brace benefit with HCPCS L8701/L8702, but still faces unresolved fee sufficiency and cash burn concerns, with operating cash outflow of ~$11.5M in 1H25 against ~$15.5M in cash and short-term investments. McClure brings over 20 years of experience, which could strengthen commercial execution and payer relationships, areas highlighted as critical swing factors in the investment thesis. However, the departure of the prior CCO and the ongoing remediation of a material weakness in internal controls underscore execution risk during this leadership transition. Financial impact is not yet quantifiable, but the appointment signals a focus on accelerating revenue conversion and coverage expansion.

Implication

If McClure successfully broadens payer coverage and streamlines documentation, she could improve cash conversion and reduce the risk of a dilutive capital raise, potentially supporting a re-rating. Conversely, a slow transition or continued high cash burn would elevate dilution risk and pressure the stock, given the constrained liquidity runway. Key metrics to monitor include quarterly operating cash flow, gross margin trajectory, and Medicare claim approval/audit outcomes under L8701/L8702. Any adverse audit trends or failure to stabilize working capital would likely shift the thesis toward a more negative stance. Success in expanding commercial and VA channel adoption could validate scale economics and move the rating toward a Buy.

Thesis delta

The appointment of a new Chief Commercial Officer is a modest positive for execution capability but does not alter the core financial challenges of negative free cash flow and unproven unit economics. We maintain a HOLD/NEUTRAL stance, with any upgrade contingent on clear evidence of improved payer coverage and reduced operating cash outflow over the next 1-2 quarters. The departure of the prior CCO adds transition risk, but also creates an opportunity for fresh strategies to address reimbursement headwinds.